SARDOCOR CORP.

Medera's clinical-stage gene therapy subsidiary, Sardocor Corp., completed Cohort A (low-dose SRD-002) and initiated Cohort B (high-dose) for HFpEF treatment, following DSMB recommendation. SRD-002, an AAV-based gene therapy, showed promising efficacy in Cohort A at six months, with additional data being collected.